These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12902171)

  • 1. The relevance of alternative RNA splicing to pharmacogenomics.
    Bracco L; Kearsey J
    Trends Biotechnol; 2003 Aug; 21(8):346-53. PubMed ID: 12902171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of microRNAs and alternative splicing in pharmacogenomics.
    Passetti F; Ferreira CG; Costa FF
    Pharmacogenomics J; 2009 Feb; 9(1):1-13. PubMed ID: 19156160
    [No Abstract]   [Full Text] [Related]  

  • 3. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq.
    Feng H; Qin Z; Zhang X
    Cancer Lett; 2013 Nov; 340(2):179-91. PubMed ID: 23196057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of using SNPs in the understanding and treatment of disease.
    Schifreen RS; Storts DR; Buller AM
    Biotechniques; 2002 Jun; Suppl():14-6, 18, 20-1. PubMed ID: 12083392
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants.
    Gaildrat P; Killian A; Martins A; Tournier I; Frébourg T; Tosi M
    Methods Mol Biol; 2010; 653():249-57. PubMed ID: 20721748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The splicing machinery is a genetic modifier of disease severity.
    Nissim-Rafinia M; Kerem B
    Trends Genet; 2005 Sep; 21(9):480-3. PubMed ID: 16039004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alternative mRNA splicing, pathology and molecular therapeutics].
    Corcos L; Solier S
    Med Sci (Paris); 2005 Mar; 21(3):253-60. PubMed ID: 15745698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative RNA splicing and drug target identification.
    Mangasarian A
    IDrugs; 2005 Sep; 8(9):725-9. PubMed ID: 16118693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics in psychiatry: genomic considerations.
    Licinio J; Wong ML
    Mol Psychiatry; 2005 Aug; 10(8):713. PubMed ID: 16044177
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction to SNPs: discovery of markers for disease.
    Weiner MP; Hudson TJ
    Biotechniques; 2002 Jun; Suppl():4-7, 10, 12-3. PubMed ID: 12083396
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomic applications in clinical drug development.
    Dracopoli NC
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S57-60. PubMed ID: 12856151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strength in numbers.
    Padma TV
    Nature; 2005 Jul; 436(7050):492-3. PubMed ID: 16089007
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple alternative splicing markers for ovarian cancer.
    Klinck R; Bramard A; Inkel L; Dufresne-Martin G; Gervais-Bird J; Madden R; Paquet ER; Koh C; Venables JP; Prinos P; Jilaveanu-Pelmus M; Wellinger R; Rancourt C; Chabot B; Abou Elela S
    Cancer Res; 2008 Feb; 68(3):657-63. PubMed ID: 18245464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.
    Pan Q; Shai O; Lee LJ; Frey BJ; Blencowe BJ
    Nat Genet; 2008 Dec; 40(12):1413-5. PubMed ID: 18978789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splice variants as cancer biomarkers.
    Brinkman BM
    Clin Biochem; 2004 Jul; 37(7):584-94. PubMed ID: 15234240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The connection between splicing and cancer.
    Srebrow A; Kornblihtt AR
    J Cell Sci; 2006 Jul; 119(Pt 13):2635-41. PubMed ID: 16787944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems approaches for pharmacogenetics and pharmacogenomics.
    Bader JS
    Pharmacogenomics; 2008 Mar; 9(3):257-62. PubMed ID: 18303961
    [No Abstract]   [Full Text] [Related]  

  • 18. Methodological and statistical issues in pharmacogenomics.
    Peters BJ; Rodin AS; de Boer A; Maitland-van der Zee AH
    J Pharm Pharmacol; 2010 Feb; 62(2):161-6. PubMed ID: 20487194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer.
    Wang Z; Lo HS; Yang H; Gere S; Hu Y; Buetow KH; Lee MP
    Cancer Res; 2003 Feb; 63(3):655-7. PubMed ID: 12566310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases.
    Petrovski S; Szoeke CE; Sheffield LJ; D'souza W; Huggins RM; O'brien TJ
    Pharmacogenet Genomics; 2009 Feb; 19(2):147-52. PubMed ID: 19077679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.